



TITLE:

Sodium-glucose Co-transporters: Functional Properties and Pharmaceutical Potential

AUTHOR(S):

Sano, Ryuhei; Shinozaki, Yuichi; Ohta, Takeshi

CITATION:

Sano, Ryuhei ...[et al]. Sodium-glucose Co-transporters: Functional Properties and Pharmaceutical Potential. Journal of Diabetes Investigation 2020, 11(4): 770-782

ISSUE DATE:

2020-07

URL:

<http://hdl.handle.net/2433/253526>

RIGHT:

© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd; This is an open access article under the terms of the Creative Commons Attribution - NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential

Ryuhei Sano¹, Yuichi Shinozaki¹, Takeshi Ohta^{2,*} 

¹Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Takatsuki, Japan, and ²Laboratory of Animal Physiology and Functional Anatomy, Graduate School of Agriculture, Kyoto University, Kyoto, Japan

Keywords

Antidiabetic drugs, Sodium–glucose cotransporter 1, Sodium–glucose cotransporter 2

*Correspondence

Takeshi Ohta
Tel.: +81-75-753-6325
Fax: +81-75-753-6345
E-mail address:
ota.takeshi.3a@kyoto-u.ac.jp

ABSTRACT

Glucose is the most abundant monosaccharide, and an essential source of energy for most living cells. Glucose transport across the cell membrane is mediated by two types of transporters: facilitative glucose transporters (gene name: solute carrier 2A) and sodium–glucose cotransporters (SGLTs; gene name: solute carrier 5A). Each transporter has its own substrate specificity, distribution, and regulatory mechanisms. Recently, SGLT1 and SGLT2 have attracted much attention as therapeutic targets for various diseases. This review addresses the basal and functional properties of glucose transporters and SGLTs, and describes the pharmaceutical potential of SGLT1 and SGLT2.

J Diabetes Investig 2020; 11: 770–782

doi: 10.1111/jdi.13255

INTRODUCTION

In mammals, glucose movement into and out of cells is achieved by glucose transporters (GLUTs) on the cell membrane. GLUTs are divided into two structurally and functionally distinct types: (i) GLUTs, which operate by facilitated diffusion^{1,2}; and (ii) sodium–glucose cotransporters (SGLTs), which actively transport glucose against the concentration gradient by coupling with sodium^{3,4}. GLUTs are located in all body cells to facilitate transport of glucose into the cells, and the concentrations of glucose into and out of the cells become equal with GLUTs operation¹. In the SGLTs, which comprise a family of at least six different isoforms in humans, glucose and sodium are simultaneously cotransported into the cells using the sodium concentration gradient⁵. Of these SGLTs, SGLT1 and SGLT2 have been frequently investigated, because they play key roles in the transport of glucose and sodium across the brush border membrane of intestinal and renal cells^{3,6}.

In the intestinal epithelium, glucose influx into the epithelial cells is catalyzed by SGLT1 located in the apical membrane, and the glucose flows into the circulation through GLUT2 located in the basolateral membrane^{5,7}. Also, the two types of transporter, GLUTs and SGLTs, work together in the renal tubular cells, with the SGLTs (SGLT2 and SGLT1) transporting glucose into the tubular cells across the apical membrane, and

the GLUTs (GLUT2 and GLUT1) transporting the glucose across the basolateral membrane into the blood circulation^{7,8}.

Recently, SGLT2 inhibitors have been developed, based on a new concept of antidiabetic action by inhibiting renal glucose reabsorption and increasing glucose excretion into urine. SGLT2 inhibitors reduce glucotoxicity by lowering blood glucose, and a decrease in cardiovascular death and the renal protective effects have been reported by large-scale clinical trials⁹. Furthermore, SGLT1 is responsible for glucose absorption in the small intestine and for reabsorption of the part of the filtered glucose load in the kidney¹⁰, and might be an attractive target for the maintenance of good glycemic control and improvement of renal dysfunction^{7,11}. In this review, we first present an outline summary of glucose transporters: GLUTs and SGLTs. We then focus on SGLT1 and SGLT2, and describe the functional properties and the pharmacological potential, including new insights.

BASAL PROPERTIES IN GLUTS

The facilitative glucose transporters, GLUTs, use the diffusion gradient of glucose or other sugars across cell membranes, each with unique substrate specificities, kinetic profile and expression profile in tissues⁴. GLUTs are divided into three classes by the similarity of amino acid sequence: class I facilitative transporters, GLUT1–4; class II facilitative transporters, GLUT5, 7, 9 and 11; and class III facilitative transporters, GLUT6, 8, 10, 12 and a proton myo-inositol cotransporter/GLUT13^{2,4,5}.

Received 3 January 2020; revised 6 March 2020; accepted 13 March 2020

Among the class I facilitative transporters, GLUT1 has ubiquitous expression, with abundant expression in the brain and erythrocytes, and moderate expression in fat, muscle and the liver^{4,12–14}. GLUT1 is responsible for constitutive or basal glucose uptake in the cells and can transport aldose, including pentose and hexose^{1,15}. GLUT2 is expressed in pancreatic β -cells, the liver, kidney and small intestine. In rodent β -cells, GLUT2 plays a key role in the glucose-sensing mechanism due to the low affinity and high capacity^{16,17}. In contrast, in human β -cells, GLUT1 is primarily expressed, and GLUT2 is expressed at an extremely low level¹⁸. In the liver, GLUT2 is expressed on the sinusoidal membrane and enables the bidirectional transport of glucose¹. The GLUT2 in the kidney and small intestine is responsible for the movement of glucose out of absorptive epithelial cells into the blood circulation¹⁶. GLUT3 has a high affinity for glucose, and is known for its specific expression in neurons, in particular the brain. GLUT3 is also expressed in other cells having specific glucose requirements, such as sperm cells and embryos^{5,19,20}. Insulin-responsive glucose transporter GLUT4 is expressed in skeletal muscle, adipose tissue and the heart, and is also found in the brain^{1,21}. When insulin binds to the insulin receptors, the GLUT4 moves to the cell membrane and facilitates glucose transport into the cells.

Among the class II facilitative transporters, GLUT5, which is the specific transporter for fructose, is predominantly expressed in the small intestine, testes and kidneys^{4,22}. In the intestine, GLUT5 is responsible for transport of hexose from the villus epithelium with SGLT1. The hexose in the cell leaves the epithelium through GLUT2 located in the basolateral membrane¹⁶. GLUT7 is primarily expressed in the small intestine and colon, and works as a facilitated hexose transporter²³. GLUT9 is highly expressed in the kidney and liver². In the human kidney, GLUT9 is expressed in proximal convoluted tubules, and in rodents, it is expressed in distal connecting tubules^{24,25}. GLUT9 is reportedly a urate transporter, and some mutations in its sequence induce hypouricemia²⁶. GLUT9 is also known as voltage-driven urate transporter 1 on the basolateral membrane^{27,28}. Two splice variants of GLUT11, long and short forms (503 and 493 amino acid residues), are expressed in a tissue-specific manner^{29,30}, and hexose, glucose or fructose is transported. The short form of GLUT11 is predominantly expressed in heart and skeletal muscle, and the long form is detected in the liver, lung, trachea and brain^{29,30}.

As for the class III facilitative transporters, GLUT6, which is a hexose transporter protein, is highly expressed in the brain, spleen and leukocytes⁴. GLUT8 is mainly expressed in the testis, and lower expressions of messenger ribonucleic acid (mRNA) were detected in other organs, including insulin-sensitive tissues⁵. GLUT8 has been identified as an insulin-responsive glucose transporter, and reportedly has a role in glucose uptake in the mammalian heart, along with GLUT4³¹. GLUT10 plays a role in glucose homeostasis control, and in humans, it has a higher mRNA level in the liver and pancreas³². GLUT12, which can facilitate transport of a variety of hexose, is

expressed in the heart, small intestine, prostate and insulin-sensitive tissues, including skeletal muscle and fat³³. Proton myo-inositol cotransporter/GLUT13 has been identified as a proton myo-inositol cotransporter, and is highly expressed in glial cells and some neurons, suggesting that proton myo-inositol cotransporter/GLUT13 might be responsible for myo-inositol metabolism regulation in the brain^{34,35}.

OVERVIEW OF SGLTs

SGLTs constitute a large family of membrane proteins related to various transports of glucose, amino acids, vitamins and some ions across the apical membrane of the lumen side, including in the small intestine and renal tubules. In humans, six different isoforms have been reported, and two transporters, SGLT1 (solute-carrier [SLC]5A1) and SGLT2 (SLC5A2) proteins, have been widely studied³⁶. SGLT1 was discovered by expression cloning in 1987³⁷, and SGLT2 was identified by homology screening in 1994³⁸. GLUTs equilibrate the glucose levels on both sides of the plasma membrane, because the glucose gradient across the membrane is the driving force, whereas SGLT2 can exert differences in glucose concentration, because the transmembrane sodium gradient is the driving force for glucose uptake^{3–5}.

SGLT1 is responsible for glucose absorption in the small intestine, whereas SGLT2 is responsible for glucose reabsorption in the kidney (Table 1)^{38,39}. Considering the physiological functions of SGLT1 and SGLT2, drug recovery research targeting the transporters is reasonable. In 1987, phlorizin, an inhibitor of SGLT1 and SGLT2, was reported to reverse experimental diabetes in partially pancreatectomized rats⁴⁰. SGLT inhibitors have been developed using phlorizin as a lead compound^{7,41,42}, resulting in the development of SGLT2 inhibitors, which have been successfully launched for the market^{42,43}.

As for the other SGLTs, SGLT3 (gene name: *SLC5A4*), which is expressed in the intestine, spleen, liver, kidney, skeletal muscle and cholinergic neurons, is not a functional SGLT, and seems to act as a glucose sensor in the plasma membrane of cholinergic neurons⁴⁴. There are only a few reports on the other SGLTs: SGLT4, SGLT5 and SGLT6. SGLT4 (gene name: *SLC5A9*) is expressed in the small intestine, kidneys, liver, lung, brain, trachea, uterus and pancreas; SGLT5 (gene name: *SLC5A10*) is expressed only in the kidneys; and SGLT6 (gene name: *SLC5A11*) is considered to be a low-affinity D-glucose transporter in the small intestine^{39,45}. Physiological roles of these SGLTs remain unknown.

Basal properties of SGLT1

The SGLT1 protein, encoded by the *SLC5A* gene on chromosome 22q13.1, is composed of 664 amino acids, comprising 14 transmembrane α -helical domains, a single glycosylation site between transmembrane helices 5 and 6, and two phosphorylation sites, between transmembrane helices 6 and 7, and between 8 and 9^{39,45,46}. The NH₂ and COOH terminals are located in extracellular and intracellular membranes, respectively, and the glucose-

Table 1 | Tissue expression and biochemical characteristics of sodium–glucose cotransporter 1 and sodium–glucose cotransporter 2

Characteristics	SGLT1	SGLT2
Site	Mostly in small intestine some kidney, heart, brain etc.	Mainly in kidney
Renal location	S3 segment of proximal tubules	S1 and S2 segments of proximal tubules
Sugar selectivity	Glucose = galactose	Glucose > galactose
Sodium/glucose stoichiometry	1:2	1:1
Affinity for glucose	High (0.5 mmol/L)	Low (2 mmol/L)
Glucose transport capacity	Low	High

SGLT, sodium–glucose cotransporter.

binding domain is supposed to include amino acid residues 457–460^{45,47}. SGLT1 is a high-affinity transporter for glucose (Michaelis–Menten constant [K_m] = 0.4 mmol/L) and galactose, whereas fructose is not transported^{39,48,49}. Two sodium ions are transported through the SGLT1 for each glucose molecule, and this cotransporter is allowed to transport glucose into the cells against its concentration gradient⁴.

SGLT1 mRNA expression has been detected by reverse transcription polymerase chain reaction in the following tissues in humans: small intestine, kidney, skeletal muscle, liver, lung, heart, trachea, prostate, testis, cervix of the uterus, stomach, mesenteric adipose tissue, pancreatic α -cells, colon and brain^{50–53}. SGLT1 protein expression has been localized to the apical brush border of the small intestine and the late proximal tubules, and has also been detected in the following tissues in humans: salivary gland, liver, lung, skeletal muscle, heart and pancreatic α -cells^{37,53–55}.

SGLT1 reportedly exerts the transport activity by many molecular regulations, including protein kinases. SGLT1 contains strain-specific regulation sites by protein kinase A (PKA) and protein kinase C (PKC): one PKA site in humans and rabbit, none in rat; five consensus PKC sites in humans and rats, and four sites in rabbits^{56,57}. PKA activation led to an increase in the number of SGLT1 proteins in the membrane of the small intestine in rats⁵⁸, and PKA activator, 8-bromo-cyclic adenosine monophosphate, or forskolin increased the SGLT capacity and the SGLT1 activity in the plasma membrane^{56,58}. The expression and activity of SGLT1 is positively regulated by PKA activity, and the effects on SGLT1 activation was inhibited by PKA inhibitor, H-89^{59,60}. PKC-mediated effects on SGLT1 are also reported, but obvious species differences are admitted and the effects are controversial. PKC activation decreased the SGLT1 transport capacity in rats and rabbits, but increased the capacity in humans⁵⁶.

In other reports, adenosine monophosphate-activated protein kinase activation increased maximal sodium-dependent glucose transport^{61,62}, knockout of the serum- and glucocorticoid-inducible kinase 3 caused a decrease of intestinal SGLT1 activity⁶³, and Ste20p-related proline alanine-rich kinase caused a decrease of SGLT1 abundance in the plasma membrane⁶⁴.

Intestinal SGLT1 activity and expression are regulated by dietary carbohydrate content. The SGLT1 activity and expression increased in mice, rats and sheep fed a high-sugar diet⁶⁵,

and is maintained by the presence of luminal nutrients in the human intestine⁶⁶. In addition, SGLT1 activity and expression are related to a diurnal rhythm that correlates waking hours with the highest expression of SGLT1^{67,68}.

Basal properties of SGLT2

The SGLT2 protein, encoded by SLC5A2, is composed of 672 amino acids and its NH₂ and COOH termini are extracellular⁴⁶. The K_m values in human SGLT2 for glucose and sodium are 2 and 25 mmol/L, respectively, and, differently from SGLT1, SGLT2 is a low-affinity and high-capacity glucose transporter^{39,51}. SGLT2 is predominantly expressed in the kidney of rodents and humans, and low mRNA expressions were detected in the mammary glands, testis, liver, lung, intestine, skeletal muscle, spleen and cerebellum^{39,51,52,69,70}. Also, SGLT2 is reportedly expressed in pancreatic α -cells and related to glucagon secretion⁵³. SGLT2 is localized in the luminal membrane of the segment (S)1 and S2 segments of renal proximal tubules in humans and rodents, whereas SGLT1 is localized in the luminal membrane of the S3 segment^{39,52,70,71}. SGLT2 is mainly responsible for glucose reabsorption in nephron, and $\geq 80\%$ of the filtered glucose is reabsorbed in the S1 and S2 segments of the proximal tubules through SGLT2^{45,72}.

Protein kinase A and PKC activation increased glucose uptake by 225 and 150%, respectively, in human embryonic renal cells expressing SGLT2⁷³. As for the mechanisms, the PKA-mediated effect might be related to an increased rate of vesicle fusion with the membrane; however, no such mechanism was found on the PKC-mediated effect. Also, SGLT2 expression reportedly increased through the activation of exchange protein directly activated by cyclic adenosine monophosphate/PKA through extracellular signal-regulated kinase/p38 and mitogen-activated protein kinase^{73,74}. In the renal pig cell line, interleukin-6 and tumor necrosis factor- α increased SGLT2 mRNA and protein expressions⁷⁵, and similarly, the phosphorylation of transforming growth factor- β 1 and the downstream transcription factor, smad3, increased the SGLT2 protein level in human renal proximal tubular cells⁷⁶.

Functional properties of SGLTs in the small intestine

SGLT1 in the small intestine is localized in the apical cell membrane composing brush border (Figure 1)^{6,52,54}. SGLT1 is

responsible for the transport of glucose or galactose from the lumen into the epithelial cells, whereas the facilitative transporter, GLUT2, is subsequently responsible for the transport of glucose from the basolateral membrane into the blood circulation^{77,78}.

The level of SGLT1 expression provides the capacity for glucose absorption and undergoes short-term and long-term regulations depending on the luminal nutrients^{65,66}. A high-glucose diet or a high-sodium diet reportedly increases the level of SGLT1 expression in the small intestine^{65,66}. Also, an increase in the luminal glucose concentrations induces GLUT2 translocation to the brush border membrane^{78,79}.

The SGLT1 expression in the small intestine is reportedly increased in diabetes, which is considered to be related to the response to greater dietary glucose intake. Intestinal SGLT1

mRNA expression increased in diabetic animal models, such as streptozotocin-induced diabetic models and Otsuka Long-Evans Tokushima Fatty rats^{80,81}. In type 2 diabetes patients, the intestinal SGLT1 mRNA and protein expressions in the brush border membrane were higher, and also the intestinal glucose uptake was elevated⁸². The upregulation of SGLT1-mediated glucose uptake in the small intestine is considered to induce the rapid postprandial hyperglycemia in diabetes^{83,84}.

Functional properties of SGLTs in the kidney

In the kidney, glucose is transported through the apical membrane of the proximal convoluted tubule by SGLT2 and SGLT1, and exits through the basolateral membrane of the proximal tubule by the facilitative transporters GLUT2 and GLUT1^{39,85}. SGLT2 is expressed in the upper part of the proximal tubule,




Figure 1 | Glucose handling through sodium–glucose cotransporter (SGLT)1 and SGLT2. In the small intestine, dietary glucose is mainly absorbed by SGLT1 on the brush border membrane. SGLT1 has a high-affinity (Michaelis–Menten constant [K_m] = 0.4 mmol/L) for glucose, and transports sodium and glucose with a 2:1 stoichiometry. In the kidney, filtered glucose by the renal glomerulus is reabsorbed by SGLT2 and SGLT1 expressed in the luminal membrane of the segment (S1 and S2 segments, and S3 segment of proximal tubules, respectively). The affinity of SGLT2 for glucose is lower (K_m = 2 mmol/L), and transport of sodium and glucose by SGLT2 occurs with a 1:1 stoichiometry. GLUT, glucose transporter.

S1 and S2 segments, whereas SGLT1 is expressed in the downward part of the proximal tubule, the S3 segment in humans and rodents (Figure 1)^{52,71,86}.

In the capacity of filtered glucose reabsorption in euglycemia, SGLT2 exerts the main function, showing the aforementioned $\geq 80\%$ glucose reabsorption, whereas SGLT1 reabsorbs the remaining glucose or approximately 5% of the filtered glucose^{77,86,87}. As a point to be noted, the coupling ratio of glucose and sodium is different between the two cotransporters: SGLT2 transports glucose and sodium in a 1:1 ratio, whereas SGLT1 transports glucose and sodium in a 1:2 ratio^{38,39}. The transport property of SGLT2 enhances the concentrating power to reabsorb the glucose delivered to the distal part S3 segment of the proximal tubule⁴⁹. Furthermore, it is reported that SGLT1 prepares the highly reserved ability of glucose reabsorption^{72,87,88}. When pharmacological SGLT2 inhibition induces the glucose flow downstream in the distal proximal tubule, SGLT1 can compensate for the reabsorption of glucose. As a result, euglycemic humans treated with SGLT2 inhibitors maintained a fractional glucose reabsorption of 40–50%^{72,87}, and the mean value of fractional glucose reabsorption in euglycemic SGLT2 knockout (KO) mice was 36%⁸⁶. In wild mice, SGLT2 inhibitor, empagliflozin, dose-dependently increased the urinary glucose excretion, whereas the dose–response curve was shifted leftward and the maximum response doubled in SGLT1 KO mice⁸⁷. The compensatory effect of SGLT1 is also supported by studies in SGLT1/SGLT2 double KO mice^{89,90} and SGLT1 KO mice treated with SGLT2 inhibitor⁸⁷. Sustained hyperglycemia, which induces exceeding of the transport capacity of the proximal SGLT2, increased the glucose flow to the distal proximal tubule and enhanced the SGLT1-mediated glucose reabsorption⁷. The reserved ability of glucose reabsorption and compensatory effect of SGLT1 are notable properties in consideration of the physiological function.

In type 1 and type 2 diabetes animal models, the renal SGLT2 protein level was reportedly increased^{42,91}, whereas the reported results for renal SGLT1 levels are controversial. Streptozotocin rats showed increased mRNA and protein expressions of SGLT1 in the renal cortex^{92,93}. Also, renal SGLT1 mRNA expression in Zucker fatty rats was increased⁹⁴. In *ob/ob* mice, the renal membrane SGLT1 protein level was increased, but the mRNA expression was decreased⁹⁵. In contrast, it was reported that the renal membrane SGLT1 protein level was decreased in diabetic Akita mice⁹⁶. SGLT2 and SGLT1 properties in renal glucose reabsorption in euglycemic condition are well understood; however, those properties in the diabetic state remain poorly understood, and in particular, a better understanding of the physiological significance in the renal SGLT1 regulation is a pivotal subject for the future.

Functional properties of SGLTs in the heart

The localization of SGLT1 protein was found in capillaries of the heart in humans and rats^{52,97}, whereas the expression was not found in capillaries of the small intestine⁹⁷. Also, SGLT1

was reportedly expressed in the cell membrane of cardiomyocytes in humans and mice^{98,99}. Thus, cardiac SGLT1 might be involved in glucose transport from capillaries into the cardiomyocytes. In contrast, SGLT2 is not expressed in the heart. In the heart, two facilitated glucose transporters, GLUT1 and GLUT4, play a primary role in glucose uptake: GLUT1 for basal glucose uptake, and GLUT4 for insulin-dependent glucose uptake¹⁰⁰. In consideration of the physiological roles of SGLT1 in the heart, the involvement with the facilitated glucose transporters is essential and cannot be bypassed.

Cardiac SGLT1 mRNA expression is reportedly increased in patients with type 2 diabetes and diabetic cardiomyopathy¹⁰¹. In streptozotocin diabetic rats, GLUT4 mRNA and protein expressions were decreased, whereas GLUT1 mRNA expression was not significantly changed^{102,103}. The reduction of cardiac GLUT4 activity led to a decrease of glucose uptake and development of diabetic cardiomyopathy, whereas the physiological roles of GLUT1 in the heart remain unclear^{104–106}.

A recent study reported that chronic cardiac overexpression of SGLT1 in mice led to pathological cardiac hypertrophy and left ventricular failure, and cardiac knockdown of SGLT1 attenuated the disease phenotype¹⁰⁷. In contrast, a recent study also reported that dual SGLT1/SGLT2 inhibitor exacerbated cardiac dysfunction after experimental myocardial infarction in rats¹⁰⁸. Considering that SGLT2 is not expressed in the heart, this effect might be linked to SGLT1 inhibition. Whether cardiac SGLT1 inhibition exerts protective effects on cardiovascular disease still remains unclear. Further research is required.

Functional properties of SGLTs in the brain

SGLT1 mRNA expression was found in the brains of humans, rabbits, pigs and rodents^{109–111}. In rabbits and pigs, SGLT1 mRNA expression was found in neurons of the frontal cortex, Purkinje cells of the cerebellum and neurons of the hippocampus⁵⁰. In rodents, SGLT1 mRNA expression was found in neurons of the brain cortex, hippocampus, hypothalamus, corpus striatum and cerebellum^{50,111}. The SGLT1 protein was reportedly expressed in small vessels of the rodent brain¹⁰⁹. Also, a radioactively labeled SGLT1 selective glucose analog could not pass the blood–brain barrier, suggesting that SGLT1 is only localized in the luminal membrane of endothelial cells⁵⁰. In consideration of the localization and function of SGLT1, SGLT1 in the brain might play a key role as an energy supply source for neurons on increased glucose demand, such as in hypoxemia and hypoglycemia.

Functional properties of SGLTs in other organs

There are some reports of SGLT1 in the lung, liver, pancreas and T lymphocytes. SGLT1 mRNA was detected in the trachea, bronchi and lung tissue in humans^{51,52}, and SGLT1 protein was detected in alveolar type 2 cells, and in the luminal membrane of Clara cells in bronchioles in humans and rats⁵². SGLT1-mediated glucose uptake might be responsible for fluid absorption, and provides energy for the production of

surfactants in alveolar type 2 cells, and for mucin and surfactants in Clara cells.

SGLT1 mRNA was detected in the liver and gallbladder in humans⁵¹, and SGLT1 protein was detected in the apical membrane of bile duct epithelial cells in humans and rats^{52,71}.

Small amounts of SGLT1 mRNA were detected in the pancreas of humans, and SGLT1 mRNA and protein expressions were found in pancreatic α -cells of humans and mice^{51,53}. Also, SGLT1 mRNA expression was found in activated T lymphocytes of mice¹¹². Physiological roles of SGLT1 in the liver, pancreas and T lymphocytes are not well understood.

THERAPEUTIC POTENTIAL OF SGLT1 AND SGLT2 INHIBITION

The therapeutic potential of selective SGLT2 inhibitors as an antihyperglycemic strategy has been well established. In contrast, the therapeutic potential, including efficacy and safety, of dual SGLT2/SGLT1 inhibitor or selective SGLT1 inhibitor remains less clear (Table 2).

SGLT2 inhibitors

Selective SGLT2 inhibitors – dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, luseogliflozin and tofogliflozin – have been approved for the treatment of type 2 diabetes¹¹³. These SGLT2 inhibitors reduce plasma glucose levels by a different mechanism than other antidiabetic drugs, involving an increase of the renal glucose excretion through SGLT2 in the proximal tubule leading to diminished glucose toxicity. In contrast, mechanisms of other drugs are as for metformin: inhibition of gluconeogenesis in the liver; sulfonylurea derivatives, glucagon-like peptide (GLP)-1 analogs and dipeptidyl peptide-4 inhibitors: increase of insulin secretion in the pancreas; and thiazolidinediones: enhancement of insulin sensitivity. These SGLT2 inhibitors have different selectivity for inhibition of SGLT2 versus SGLT1. SGLT2/SGLT1 selectivity is $\geq 1,000$ -fold higher in dapagliflozin, empagliflozin, luseogliflozin and tofogliflozin, whereas the selectivity of canagliflozin and ipragliflozin is lower, at 190- and 250-fold, respectively¹¹³.

Table 2 | Preclinical and clinical sodium–glucose cotransporter 1, sodium–glucose cotransporter 2 and dual sodium–glucose cotransporter 1/2 inhibitors

Selective SGLT1 inhibitors	Selective SGLT2 inhibitors	Dual SGLT1/2 inhibitors
KGA-2727	Dapagliflozin	Sotagliflozin
GSK-1614235 (mizagliflozin)	Canagliflozin	Licogliflozin
LX2761	Empagliflozin	
JTT-662	Ipragliflozin	
	Luseogliflozin	
	Tofogliflozin	
	Ertugliflozin	

SGLT, sodium–glucose cotransporter.

In preclinical studies in diabetic animal models, the SGLT2 inhibitors decreased fasting and non-fasting glucose levels, hemoglobin A1c levels, and blood pressure, and improved glucose intolerance^{114–117}. Furthermore, SGLT2 inhibitors have a different mechanism from the other antidiabetic drugs, as described above, and can be used in combination with those drugs, as well as in monotherapy for the treatment of type 2 diabetes^{118–122}.

Recent studies reported that SGLT2 inhibitors had a renal protective effect in animal models of diabetic nephropathy^{122–124}. The renal protective effects of SGLT2 inhibitors also have been shown in clinical trials^{9,125,126}. The mechanism of action is speculated as follows: SGLT2 inhibitor increases the amount of sodium delivery to the distal tubule by suppressing sodium absorption in the proximal tubule. As a result, the tubuloglomerular feedback through the macula densa is activated, and this allows afferent arteriolar contraction and normalizes the glomerular filtration rate¹²⁷.

SGLT1 inhibitors

Postprandial hyperglycemia is a risk factor for cardiovascular failure and diabetic microangiopathy, including retinopathy^{128–130}. As glucose absorption from the small intestine is mostly mediated by SGLT1, an improvement of postprandial hyperglycemia with SGLT1 inhibitor would definitely be a useful therapy. In diabetic rats, a single dose of KGA-2727, a selective SGLT1 inhibitor, improved postprandial hyperglycemia, and its chronic administration reduced hemoglobin A1c levels¹³¹, suggesting that SGLT1 inhibition might maintain good glycemic control for the long term. In an oral glucose tolerance test with KGA-2727, plasma insulin levels, as well as plasma glucose levels, were reduced, and protective effects on the pancreas are also expected.

Recent studies reported that SGLT1 KO mice and mice treated with phloridzin had lower plasma total GLP-1 levels 5 min after glucose challenge than wild-type mice and control mice, respectively^{77,132}. This result suggests that SGLT1 is required to trigger GLP-1 secretion in the early phase after glucose stimulation. In contrast, another study reported that SGLT1 KO mice had high plasma total GLP-1 levels from 30 min to 6 h after a glucose-containing meal⁸⁹. The increase of plasma total GLP-1 in the late phase after a meal was also observed in healthy humans treated with SGLT1 inhibitor⁸⁴ and patients with type 2 diabetes treated with SGLT1/2 inhibitor⁸³. One possible mechanism of delayed GLP-1 release is fermentation of glucose to short-chain fatty acids (SCFAs). SGLT1 inhibition in the early intestine reduces glucose absorption and thereby increases glucose delivery to the more distal parts of the small intestine, where glucose is used by the microbiome to form SCFAs. SCFAs induce glucagon-like peptide-1 secretion through G protein-coupled receptors, including G protein-coupled receptor 41 and G protein-coupled receptor 43¹³³. From the above, although SGLT1 inhibition reduces glucose-stimulated GLP-1 release in the early phase, SCFAs generated by fermentation of

glucose induce GLP-1 release in the late phase, suggesting that SGLT1 inhibitor increases net circulating GLP-1 levels.

As a concerning point, in the small intestine, the SGLT1 inhibitor is considered to induce gastrointestinal side-effects, including diarrhea, but no serious gastrointestinal side-effects were observed in the treatment of selective SGLT1 inhibitors, GSK-1614235 and KGA-2727, or a dual SGLT1/SGLT2 inhibitor, sotagliflozin^{83,84,134}.

The SGLT1 inhibitors induce a delay of absorption of monosaccharides and thus their retention, and the SGLT1 inhibitors might improve the intestinal condition in diabetes patients through changes in gut microbiota. An increase in colonic microbial production of propionate with increased

glucose exposure reportedly contributed to positive intestinal metabolic effects¹⁰.

SGLT1 is expressed in the brush border membrane of the S3 segment of proximal tubule in the kidney, and reabsorbs glucose that escapes from SGLT2-mediated reabsorption in the S1 and S2 segments^{39,52}. Studies on SGLT2 KO mice and selective SGLT2 inhibitors described the renal transport capacity of SGLT1, showing that the SGLT1-mediated glucose reabsorption is maintained at 40–50% on inhibition of SGLT2 under euglycemic conditions (Figure 2)⁸⁷. Inhibition of SGLT2 under the conditions of prolonged and severe hyperglycemia that exceeds the transport capacity of SGLT2 activates the full renal transport capacity of SGLT1, and SGLT1 exerts a compensatory




Figure 2 | Capacity of sodium–glucose cotransporter (SGLT)1 and SGLT2 for filtered glucose reabsorption under euglycemic conditions. Under euglycemic conditions, most filtered glucose is reabsorbed by SGLT2 expressed in the segment (S)1 and S2 segments of proximal tubules, and the remaining is reabsorbed by SGLT1 expressed in the S3 segment of proximal tubules, resulting in no glucose being detected in the urine. Complete suppression of transport activity of SGLT1 (e.g., SGLT1 knockout [KO] or inhibition) only slightly increases the urinary glucose excretion, because most filtered glucose is reabsorbed by SGLT2. If SGLT2 is absent (e.g., SGLT2 KO or inhibition), SGLT1 reabsorbs 40–50% of filtered glucose. If both SGLT1 and SGLT2 are absent (e.g., SGLT1/2 double KO [DKO] or dual inhibition), almost all of the filtered glucose is excreted in the u-rine.

function in renal reabsorption of glucose. Therefore, the combination therapy of an SGLT1 inhibitor and an SGLT2 inhibitor or a dual SGLT1/SGLT2 inhibitor is expected to induce significantly greater glucosuria and glycemic control than either an SGLT1 or SGLT2 inhibitor alone^{87,89,135}. Also, a stronger effect of dual SGLT1/SGLT2 inhibition on blood glucose levels was observed in mice with modest hyperglycemia, as well as those with euglycemia^{87,89}. Thus, the combined effects of dual SGLT1/SGLT2 inhibition might induce synergistic effects on the early and distal proximal tubules.

Although selective SGLT1 inhibitors are not on the market yet, some compounds (e.g., LX2761 and JTT-662) are under development for the treatment of diabetes.

CONCLUSION AND PERSPECTIVE

In this review, we described the basal properties of GLUTs and SGLTs, and also the functional properties of SGLT1 and SGLT2, and focused on the pharmacological potential of SGLT1 or SGLT2 inhibition alone, and the dual inhibition of SGLT1 and SGLT2. These glucose transporters have diverse multiple functions, and are attractive as therapeutic targets for metabolic diseases.

In basic studies of the kidney in SGLT2 KO mice and using an SGLT2 inhibitor, a high reserved ability of glucose reabsorption has been disclosed. Six selective SGLT2 inhibitors have been approved for treatment of diabetes, and the usefulness is widely admitted.

Based on the phenotype of loss-of-function of the SGLT1 gene in humans and mice, it is clear that SGLT1 is the main transporter of glucose absorption in the small intestine. As described above, it is expected that SGLT1 inhibitors would improve postprandial hyperglycemia in diabetes patients by reducing glucose absorption in the small intestine. This mechanism of action would be beneficial, particularly in diabetes patients with declining renal function, because SGLT2 inhibitors are less effective in such patients.

A dual SGLT1/SGLT2 inhibitor or a combination of an SGLT1 inhibitor and SGLT2 inhibitor might be good option for the treatment of diabetes, because dual inhibition leads to blockade of both intestinal and renal glucose absorption, thus lowering blood glucose levels robustly. Combined treatment of SGLT1 inhibitor and dipeptidyl peptide-4 inhibitor might also be a good strategy, because the combination could effectively increase active GLP-1 levels.

Diabetes is a leading cause of end-stage kidney disease and cardiovascular disease. Despite the emergence of a large variety of antihyperglycemic agents, it is still difficult to maintain good glycemic control with monotherapy over a long-term period. These agents also have potential risks and side-effects (e.g., hypoglycemia, ketoacidosis and more). For these reasons, other antihyperglycemic agents with different mechanisms of action are required. Inhibition of SGLT1 or dual inhibition of SGLT1/2 are novel therapeutic strategies for glycemic control in

diabetes patients. However, further studies are required to confirm the long-term efficiency and safety of these strategies.

ACKNOWLEDGMENT

The authors thank Dr Tomohiko Sasase for suggestions on writing this manuscript.

DISCLOSURE

Ryuhei Sano and Yuichi Shinozaki are employees of Japan Tobacco Inc. Takeshi Ohta declares no conflict of interest.

REFERENCES

1. Mueckler M. Facilitative glucose transporters. *Eur J Biochem* 1994; 219: 713–725.
2. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). *Mol Membr Biol* 2001; 18: 247–256.
3. Wright EM. Renal Na(+)-glucose cotransporters. *Am J Physiol Renal Physiol* 2001; 280: F10–F18.
4. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. *Br J Nutr* 2003; 89: 3–9.
5. Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. *JPEN J Parenter Enteral Nutr* 2004; 28: 364–371.
6. Hirayama BA, Wong HC, Smith CD, *et al.* Intestinal and renal Na+/glucose cotransporters share common structures. *Am J Physiol* 1991; 261: C296–C304.
7. Song P, Onishi A, Koepsell H, *et al.* Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. *Expert Opin Ther Targets* 2016; 20: 1109–1125.
8. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. *Clin J Am Soc Nephrol* 2010; 5: 133–141.
9. Wanner C, Inzucchi SE, Lachin JM, *et al.* Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med* 2016; 375: 323–334.
10. Lehmann A, Hornby PJ. Intestinal SGLT1 in metabolic health and disease. *Am J Physiol Gastrointest Liver Physiol* 2016; 310: G887–G898.
11. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. *Lancet Diabetes Endocrinol* 2013; 1: 140–151.
12. Guo X, Geng M, Du G. Glucose transporter 1, distribution in the brain and in neural disorders: its relationship with transport of neuroactive drugs through the blood-brain barrier. *Biochem Genet* 2005; 43: 175–187.
13. Aoyama M, Maejima Y, Suzuki T, *et al.* Androgen suppresses corticotropin-induced increase in plasma cortisol level but enhances the increase in plasma aldosterone level in goats. *J Vet Med Sci* 2009; 71: 281–285.

14. Jurcovicova J. Glucose transport in brain - effect of inflammation. *Endocr Regul* 2014; 48: 35–48.
15. Mueckler M, Makepeace C. Transmembrane segment 6 of the Glut1 glucose transporter is an outer helix and contains amino acid side chains essential for transport activity. *J Biol Chem* 2008; 283: 11550–11555.
16. Bell GI, Kayano T, Buse JB, *et al.* Molecular biology of mammalian glucose transporters. *Diabetes Care* 1990; 13: 198–208.
17. Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. *Am J Physiol Endocrinol Metab* 2009; 296: E985–E992.
18. De Vos A, Heimberg H, Quartier E, *et al.* Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. *J Clin Invest* 1995; 96: 2489–2495.
19. Haber RS, Weinstein SP, O'Boyle E, *et al.* Tissue distribution of the human GLUT3 glucose transporter. *Endocrinology* 1993; 132: 2538–2543.
20. Carayannopoulos MO, Xiong F, Jensen P, *et al.* GLUT3 gene expression is critical for embryonic growth, brain development and survival. *Mol Genet Metab* 2014; 111: 477–483.
21. Rayner DV, Thomas ME, Trayhurn P. Glucose transporters (GLUTs 1–4) and their mRNAs in regions of the rat brain: insulin-sensitive transporter expression in the cerebellum. *Can J Physiol Pharmacol* 1994; 72: 476–479.
22. Rand EB, Depaoli AM, Davidson NO, *et al.* Sequence, tissue distribution, and functional characterization of the rat fructose transporter GLUT5. *Am J Physiol* 1993; 264: G1169–G1176.
23. Cheeseman C. GLUT7: a new intestinal facilitated hexose transporter. *Am J Physiol Endocrinol Metab* 2008; 295: E238–E241.
24. Augustin R, Carayannopoulos MO, Dowd LO, *et al.* Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. *J Biol Chem* 2004; 279: 16229–16236.
25. Keembiyehetty C, Augustin R, Carayannopoulos MO, *et al.* Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes. *Mol Endocrinol* 2006; 20: 686–697.
26. Matsuo H, Chiba T, Nagamori S, *et al.* Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. *Am J Human Genet* 2008; 83: 744–751.
27. Anzai N, Ichida K, Jutabha P, *et al.* Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. *J Biol Chem* 2008; 283: 26834–26838.
28. Doblado M, Moley KH. Facilitative glucose transporter 9, a unique hexose and urate transporter. *Am J Physiol Endocrinol Metab* 2009; 297: E831–E835.
29. Doege H, Bocianski A, Scheepers A, *et al.* Characterization of human glucose transporter (GLUT) 11 (encoded by SLC2A11), a novel sugar-transport facilitator specifically expressed in heart and skeletal muscle. *Biochem J* 2001; 359: 443–449.
30. Wu X, Li W, Sharma V, *et al.* Cloning and characterization of glucose transporter 11, a novel sugar transporter that is alternatively spliced in various tissues. *Mol Genet Metab* 2002; 76: 37–45.
31. Maria Z, Campolo AR, Lacombe VA. Diabetes alters the expression and translocation of the insulin-sensitive glucose transporters 4 and 8 in the atria. *PLoS ONE* 2015; 10: e0146033.
32. Dawson PA, Mychaleckyj JC, Fossey SC, *et al.* Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1. *Mol Genet Metab* 2001; 74: 186–199.
33. Rogers S, Macheda ML, Docherty SE, *et al.* Identification of a novel glucose transporter-like protein-GLUT-12. *Am J Physiol Endocrinol Metab* 2002; 282: E733–E738.
34. Uldry M, Ibberson M, Horisberger JD, *et al.* Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. *EMBO J* 2001; 20: 4467–4477.
35. Di Daniel E, Mok MH, Mead E, *et al.* Evaluation of expression and function of the H(+)-myo-inositol transporter HMIT. *BMC Cell Biol* 2009; 10: 54.
36. Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. *Curr Opin Nephrol Hypertens* 2015; 24: 463–469.
37. Hediger MA, Coady MJ, Ikeda TS, *et al.* Expression cloning and cDNA sequencing of the Na(+)-glucose co-transporter. *Nature* 1987; 330: 379–381.
38. Kanai Y, Lee WS, You G, *et al.* The human kidney low affinity Na(+)-glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. *J Clin Invest* 1994; 93: 397–404.
39. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. *Physiol Rev* 2011; 91: 733–794.
40. Rossetti L, Smith D, Shulman GI, *et al.* Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. *J Clin Invest* 1987; 79: 1510–1515.
41. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. *Diabetes Obes Metab* 2012; 14: 5–14.
42. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. *Annu Rev Med* 2015; 66: 255–270.
43. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. *Am J Physiol Renal Physiol* 2015; 309: F889–F900.
44. Diez-Sampedro A, Hirayama BA, Osswald C, *et al.* A glucose sensor hiding in a family of transporters. *Proc Natl Acad Sci USA* 2003; 100: 11753–11758.
45. Wright EM, Loo DD, Hirayama BA, *et al.* Surprising versatility of Na(+)-glucose cotransporters: SLC5. *Physiology* 2004; 19: 370–376.

46. Turk E, Wright EM. Membrane topology motifs in the SGLT cotransporter family. *J Membr Biol* 1997; 159: 1–20.
47. Tyagi NK, Kumar A, Goyal P, *et al.* D-Glucose-recognition and phlorizin-binding sites in human sodium/D-glucose cotransporter 1 (hSGLT1): a tryptophan scanning study. *Biochemistry* 2007; 46: 13616–13628.
48. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. *Physiol Rev* 1994; 74: 993–1026.
49. Hummel CS, Lu C, Loo DD, *et al.* Glucose transport by human renal Na⁺/D-glucose cotransporters SGLT1 and SGLT2. *Am J Physiol Cell Physiol* 2011; 300: C14–21.
50. Poppe R, Karbach U, Gambaryan S, *et al.* Expression of the Na⁺-D-glucose cotransporter SGLT1 in neurons. *J Neurochem* 1997; 69: 84–94.
51. Chen J, Williams S, Ho S, *et al.* Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. *Diabetes Ther* 2010; 1: 57–92.
52. Vrhovac I, Balen Eror D, Klessen D, *et al.* Localizations of Na⁺(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. *Pflugers Archiv* 2015; 467: 1881–1898.
53. Bonner C, Kerr-Conte J, Gmyr V, *et al.* Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nat Med* 2015; 21: 512–517.
54. Lee WS, Kanai Y, Wells RG, *et al.* The high affinity Na⁺/glucose cotransporter. Re-evaluation of function and distribution of expression. *J Biol Chem* 1994; 269: 12032–12039.
55. Sabino-Silva R, Freitas HS, Lamers ML, *et al.* Na⁺-glucose cotransporter SGLT1 protein in salivary glands: potential involvement in the diabetes-induced decrease in salivary flow. *J Membr Biol* 2009; 228: 63–69.
56. Hirsch JR, Loo DD, Wright EM. Regulation of Na⁺/glucose cotransporter expression by protein kinases in *Xenopus laevis* oocytes. *J Biol Chem* 1996; 271: 14740–14746.
57. Wright EM, Hirsch JR, Loo DD, *et al.* Regulation of Na⁺/glucose cotransporters. *J Exp Biol* 1997; 200: 287–293.
58. Subramanian S, Glitz P, Kipp H, *et al.* Protein kinase-A affects sorting and conformation of the sodium-dependent glucose co-transporter SGLT1. *J Cell Biochem* 2009; 106: 444–452.
59. Ishikawa Y, Eguchi T, Ishida H. Mechanism of beta-adrenergic agonist-induced transmural transport of glucose in rat small intestine. Regulation of phosphorylation of SGLT1 controls the function. *Biochim Biophys Acta* 1997; 1357: 306–318.
60. Aschenbach JR, Borau T, Gabel G. Glucose uptake via SGLT-1 is stimulated by beta(2)-adrenoceptors in the ruminal epithelium of sheep. *J Nutr* 2002; 132: 1254–1257.
61. Sopjani M, Bhavsar SK, Fraser S, *et al.* Regulation of Na⁺-coupled glucose carrier SGLT1 by AMP-activated protein kinase. *Mol Membr Biol* 2010; 27: 137–144.
62. Banerjee SK, Wang DW, Alzamora R, *et al.* SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. *J Mol Cell Cardiol* 2010; 49: 683–692.
63. Sandu C, Rexhepaj R, Grahammer F, *et al.* Decreased intestinal glucose transport in the sgk3-knockout mouse. *Pflugers Archiv* 2005; 451: 437–444.
64. Elvira B, Blecua M, Luo D, *et al.* SPAK-sensitive regulation of glucose transporter SGLT1. *J Membr Biol* 2014; 247: 1191–1197.
65. Ferraris RP, Diamond J. Regulation of intestinal sugar transport. *Physiol Rev* 1997; 77: 257–302.
66. Dyer J, Hosie KB, Shirazi-Beechey SP. Nutrient regulation of human intestinal sugar transporter (SGLT1) expression. *Gut* 1997; 41: 56–59.
67. Tavakkolizadeh A, Berger UV, Shen KR, *et al.* Diurnal rhythmicity in intestinal SGLT-1 function, V(max), and mRNA expression topography. *Am J Physiol Gastrointest Liver Physiol* 2001; 280: G209–G215.
68. Pan X, Terada T, Okuda M, *et al.* The diurnal rhythm of the intestinal transporters SGLT1 and PEPT1 is regulated by the feeding conditions in rats. *J Nutr* 2004; 134: 2211–2215.
69. Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. *Curr Genom* 2007; 8: 113–128.
70. Sabolic I, Vrhovac I, Eror DB, *et al.* Expression of Na⁺-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. *Am J Physiol Cell Physiol* 2012; 302: C1174–C1188.
71. Balen D, Ljubojevic M, Breljak D, *et al.* Revised immunolocalization of the Na⁺-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. *Am J Physiol Cell Physiol* 2008; 295: C475–C489.
72. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. *Diabetes* 2013; 62: 3324–3328.
73. Ghezzi C, Wright EM. Regulation of the human Na⁺-dependent glucose cotransporter hSGLT2. *Am J Physiol Cell Physiol* 2012; 303: C348–C354.
74. Sunilkumar S, Ford SM. Elevated glucose concentration in culture media decreases membrane trafficking of SGLT2 in LLC-PK1 cells via a cAMP/PKA-dependent pathway. *Am J Physiol Cell Physiol* 2019; 316: C913–C924.
75. Maldonado-Cervantes MI, Galicia OG, Moreno-Jaime B, *et al.* Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-alpha in LLC-PK(1) cells. *J Physiol Biochem* 2012; 68: 411–420.
76. Panchapakesan U, Pegg K, Gross S, *et al.* Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy? *PLoS ONE* 2013; 8: e54442.
77. Gorboulev V, Schurmann A, Vallon V, *et al.* Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose

- absorption and glucose-dependent incretin secretion. *Diabetes* 2012; 61: 187–196.
78. Roder PV, Geillinger KE, Zietek TS, *et al.* The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. *PLoS ONE* 2014; 9: e89977.
79. Kellett GL, Brot-Laroche E, Mace OJ, *et al.* Sugar absorption in the intestine: the role of GLUT2. *Annu Rev Nutr* 2008; 28: 35–54.
80. Miyamoto K, Hase K, Taketani Y, *et al.* Diabetes and glucose transporter gene expression in rat small intestine. *Biochem Biophys Res Commun* 1991; 181: 1110–1117.
81. Fujita Y, Kojima H, Hidaka H, *et al.* Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. *Diabetologia* 1998; 41: 1459–1466.
82. Dyer J, Wood IS, Palejwala A, *et al.* Expression of monosaccharide transporters in intestine of diabetic humans. *Am J Physiol Gastrointest Liver Physiol* 2002; 282: G241–248.
83. Zambrowicz B, Freiman J, Brown PM, *et al.* LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. *Clin Pharmacol Ther* 2012; 92: 158–169.
84. Dobbins RL, Greenway FL, Chen L, *et al.* Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. *Am J Physiol Gastrointest Liver Physiol* 2015; 308: G946–954.
85. Vallon V, Sharma K. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. *Curr Opin Nephrol Hypertens* 2010; 19: 425–431.
86. Vallon V, Platt KA, Cunard R, *et al.* SGLT2 mediates glucose reabsorption in the early proximal tubule. *J Am Soc Nephrol* 2011; 22: 104–112.
87. Rieg T, Masuda T, Gerasimova M, *et al.* Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. *Am J Physiol Renal Physiol* 2014; 306: F188–F193.
88. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? *Diabetes* 2012; 61: 2199–2204.
89. Powell DR, DaCosta CM, Gay J, *et al.* Improved glycemic control in mice lacking SglT1 and SglT2. *Am J Physiol Endocrinol Metab* 2013; 304: E117–E130.
90. Powell DR, DaCosta CM, Smith M, *et al.* Effect of LX4211 on glucose homeostasis and body composition in preclinical models. *J Pharmacol Exp Ther* 2014; 350: 232–242.
91. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. *Annu Rev Physiol* 2012; 74: 351–375.
92. Vestri S, Okamoto MM, de Freitas HS, *et al.* Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. *J Membr Biol* 2001; 182: 105–112.
93. Vidotti DB, Arnoni CP, Maquigussa E, *et al.* Effect of long-term type 1 diabetes on renal sodium and water transporters in rats. *Am J Nephrol* 2008; 28: 107–114.
94. Tabatabai NM, Sharma M, Blumenthal SS, *et al.* Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. *Diabetes Res Clin Pract* 2009; 83: e27–e30.
95. Gembardt F, Bartaun C, Jarzebska N, *et al.* The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. *Am J Physiol Renal Physiol* 2014; 307: F317–F325.
96. Vallon V, Gerasimova M, Rose MA, *et al.* SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. *Am J Physiol Renal Physiol* 2014; 306: F194–F204.
97. Elfeber K, Stumpel F, Gorboulev V, *et al.* Na(+)-D-glucose cotransporter in muscle capillaries increases glucose permeability. *Biochem Biophys Res Commun* 2004; 314: 301–305.
98. Zhou L, Cryan EV, D'Andrea MR, *et al.* Human cardiomyocytes express high level of Na⁺/glucose cotransporter 1 (SGLT1). *J Cell Biochem* 2003; 90: 339–346.
99. Kashiwagi Y, Nagoshi T, Yoshino T, *et al.* Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. *PLoS ONE* 2015; 10: e0130605.
100. Schwenk RW, Luiken JJ, Bonen A, *et al.* Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. *Cardiovasc Res* 2008; 79: 249–258.
101. Banerjee SK, McGaffin KR, Pastor-Soler NM, *et al.* SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. *Cardiovasc Res* 2009; 84: 111–118.
102. Garvey WT, Hardin D, Juhaszova M, *et al.* Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. *Am J Physiol* 1993; 264: H837–H844.
103. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. *Circulation* 2007; 115: 3213–3223.
104. Liao R, Jain M, Cui L, *et al.* Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. *Circulation* 2002; 106: 2125–2131.
105. Pereira RO, Wende AR, Olsen C, *et al.* Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. *J Am Heart Assoc* 2013; 2: e000301.
106. Pereira RO, Wende AR, Olsen C, *et al.* GLUT1 deficiency in cardiomyocytes does not accelerate the transition from

- compensated hypertrophy to heart failure. *J Mol Cell Cardiol* 2014; 72: 95–103.
107. Ramratnam M, Sharma RK, D'Auria S, *et al.* Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. *J Am Heart Assoc* 2014; 3: e000899.
 108. Connelly KA, Zhang Y, Desjardins JF, *et al.* Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. *Cardiovasc Diabetol* 2018; 17: 99.
 109. Elfeber K, Kohler A, Lutzenburg M, *et al.* Localization of the Na⁺-D-glucose cotransporter SGLT1 in the blood-brain barrier. *Histochem Cell Biol* 2004; 121: 201–207.
 110. Kang L, Routh VH, Kuzhikandathil EV, *et al.* Physiological and molecular characteristics of rat hypothalamic ventromedial nucleus glucosensing neurons. *Diabetes* 2004; 53: 549–559.
 111. O'Malley D, Reimann F, Simpson AK, *et al.* Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. *Diabetes* 2006; 55: 3381–3386.
 112. Bhavsar SK, Singh Y, Sharma P, *et al.* Expression of JAK3 Sensitive Na⁺ Coupled Glucose Carrier SGLT1 in Activated Cytotoxic T Lymphocytes. *Cell Physiol Biochem* 2016; 39: 1209–1228.
 113. Koepsell H. The Na⁺-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. *Pharmacol Therap* 2017; 170: 148–165.
 114. Tahara A, Kurosaki E, Yokono M, *et al.* Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. *Eur J Pharmacol* 2013; 715: 246–255.
 115. Michel MC, Mayoux E, Vallon V. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. *Naunyn Schmiedebergs Arch Pharmacol* 2015; 388: 801–816.
 116. Qiang S, Nakatsu Y, Seno Y, *et al.* Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. *Diabetol Metab Syndr* 2015; 7: 104.
 117. Komiya C, Tsuchiya K, Shiba K, *et al.* Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. *PLoS ONE* 2016; 11: e0151511.
 118. Luippold G, Klein T, Mark M, *et al.* Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. *Diabetes Obes Metab* 2012; 14: 601–607.
 119. Kojima N, Williams JM, Takahashi T, *et al.* Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. *J Pharmacol Exp Therap* 2013; 345: 464–472.
 120. Kern M, Kloting N, Mark M, *et al.* The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. *Metabolism* 2016; 65: 114–123.
 121. Akahane K, Ojima K, Yokoyama A, *et al.* Effects of combination of mitiglinide with various oral antidiabetic drugs in streptozotocin-nicotinamide-induced type 2 diabetic rats and Zucker fatty rats. *Clin Exp Pharmacol Physiol* 2017; 44: 1263–1271.
 122. Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, *et al.* Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. *Biomed Pharmacother* 2018; 103: 59–66.
 123. Terami N, Ogawa D, Tachibana H, *et al.* Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. *PLoS ONE* 2014; 9: e100777.
 124. Shin SJ, Chung S, Kim SJ, *et al.* Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. *PLoS ONE* 2016; 11: e0165703.
 125. Wiviott SD, Raz I, Bonaca MP, *et al.* Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2019; 380: 347–357.
 126. Perkovic V, Jardine MJ, Neal B, *et al.* Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019; 380: 2295–2306.
 127. Ito M, Tanaka T. The anticipated renoprotective effects of sodium-glucose cotransporter 2 inhibitors. *Intern Med* 2018; 57: 2105–2114.
 128. Williams SB, Goldfine AB, Timimi FK, *et al.* Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans *in vivo*. *Circulation* 1998; 97: 1695–1701.
 129. Shiraiwa T, Kaneto H, Miyatsuka T, *et al.* Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. *Biochem Biophys Res Commun* 2005; 336: 339–345.
 130. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. *Am J Cardiol* 2007; 100: 899–904.
 131. Shibasaki T, Tomae M, Ishikawa-Takemura Y, *et al.* KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. *J Pharmacol Exp Therap* 2012; 342: 288–296.
 132. Moriya R, Shirakura T, Ito J, *et al.* Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. *Am J Physiol Endocrinol Metab* 2009; 297: E1358–E1365.
 133. Tolhurst G, Heffron H, Lam YS, *et al.* Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-

- protein-coupled receptor FFAR2. *Diabetes* 2012; 61: 364–371.
134. Cefalo CMA, Cinti F, Moffa S, *et al.* Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. *Cardiovascu Diabetol* 2019; 18: 20.
135. Powell DR, Smith MG, Doree DD, *et al.* LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2. *Pharmacol Res Perspect* 2015; 3: e00129.